A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition

Biochemical Journal

Volumn 415, Issue 1, 2008, Pages 97-110

  Torbett, Neil E ^a,c,d   Luna Moran, Antonio ^a   Knight, Zachary A ^a,e   Houk, Andrew ^a   Moasser, Mark ^b   Weiss, William ^a   Shokat, Kevan M ^b   Stokoe, David ^a,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Piramed Pharma   (United Kingdom)

^d Piramed Inc

^e ROCKEFELLER UNIVERSITY   (United States)

^f GENENTECH INC   (United States)

Author keywords

Breast cancer; Genetic alteration; Phosphoinositide 3 kinase inhibitor (PI3K inhibitor); Phosphorylation; Protein kinase B (PKB); S6

Indexed keywords

CELL CULTURE; CELL PROLIFERATION; CHEMICAL REACTIONS; CYTOLOGY; PHOSPHORYLATION;

BREAST CANCER; GENETIC ALTERATION; PHOSPHOINOSITIDE 3-KINASE INHIBITOR (PI3K INHIBITOR); PROTEIN KINASE B (PKB); S6;

CELLS;

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL KINASE 108; PHOSPHATIDYLINOSITOL KINASE 75; PHOSPHATIDYLINOSITOL KINASE 85; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B; PROTEIN P110; RAS PROTEIN; S6 KINASE; TGX 286; UNCLASSIFIED DRUG; ENZYME INHIBITOR; ISOENZYME; PROTEIN KINASE INHIBITOR; PROTEIN S6; PTEN PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL VIABILITY; CONTROLLED STUDY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MUTANT; MUTATION; PHARMACODYNAMICS; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; BREAST TUMOR; CELL COUNT; CELL CYCLE; CELL DEATH; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENETICS; METABOLISM; METHODOLOGY; ONCOGENE RAS; RADIATION EXPOSURE; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BREAST NEOPLASMS; CELL COUNT; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; GENES, RAS; HUMANS; ISOENZYMES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RIBOSOMAL PROTEIN S6; SIGNAL TRANSDUCTION;

EID: 51349100763     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20080639     Document Type: Article

References (52)

1. Vanhaesebroeck, B., Leevers. S. J., Ahmadi, K., Timms. J., Katso, R., Driscoll, P C., Woscholski, R., Parker, P. J. and Waterfield, M. D. (2001) Synthesis and function of 3-phosphorylated inositol lipids. Annu. Rev. Biochem. 70, 535-602
2. Vanhaesebroeck, B. and Alessi, D. R. (2000) The PI3K-PDK1 connection: more than just a road to PKB. Biochem. J. 346, 561-576
3. Sorlie, T, Tibshirani, R., Parker, J., Hastie, T, Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S. et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U.S.A. 100, 8418-8423
4. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A. et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712
5. Mills, G. B., Lu, Y., Fang, X., Wang, H., Eder, A., Mao, M., Swaby. R., Cheng, K. W., Stokoe, D., Siminovitch, K. et al. (2001) The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin. Oncol. 28, 125-141
6. Samuels, Y., Wang, Z., Bardelli, A.. Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M,, Riggins, G. J. et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554
7. Ikenoue, T., Kanai, F, Hikiba, Y., Obata, T., Tanaka, Y., Imamura, J., Ohta, M., Jazag, A., Guleng, B., Tateishi, K. et al. (2005) Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 65, 4562-4567
8. Kang, S,, Bader, A. G. and Vogt, P. K. (2005) Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Nall. Acad. Sci. U.S.A. 102, 802-807
9. Bachman, K. E., Argani, P, Samuels, Y., Silliman, N., Ptak, J., Szabo, S., Konishi, H., Karakas, B., Blair, B. G.. Lin, C. et al. (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther. 3, 772-775
10. Campbell. I. G., Russell. S. E., Choong, D. Y., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S., Cristiano. B. E., Pearson, R. B. and Phillips, W. A. (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64, 7678-7681
11. Lee, J. W., Soung, Y. H., Kim, S. Y., Lee, H. W., Park, W. S., Nam, S. W., Kim, S. H., Lee. J. Y, Yoo, N. J. and Lee, S. H. (2005) PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24, 1477-1480
12. Saal, L. H., Holm, K., Maurer, M., Memeo. L., Su, T., Wang, X., Yu, J. S., Malmstrom, P. O., Mansukhani, M., Enoksson, J. et al. (2005) PIK3CA mutations correlate with hormone receptors, node metastasis. and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 65, 2554-2559
13. Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J. P., Tong, F. et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515-527
14. Lacroix, M. and Leclercq, G. (2004) Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res. Treat. 83, 249-289
15. Cools, J,, DeAngelo, D. J., Gotlib, J., Stover, E. H., Legare, R. D., Cortes, J., Kutok, J., Clark, J., Galinsky, I., Griffin, J. D. et al. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348, 1201-1214
16. Norman, B. H., Shih, C., Toth, J. E,, Ray, J. E., Dodge, J. A., Johnson, D. W., Rutherford, P. G., Schultz, R. M., Worzalla, J. F. and Vlahos, C. J. (1996) Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs. J. Med. Chem. 39, 1106-1111
17. Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B. et al. (2006) A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 125, 733-747
18. Finan, P. M. and Thomas, M. J. (2004) PI 3-kinase inhibition: a therapeutic target for respiratory disease. Biochem. Soc. Trans. 32, 378-382
19. Knight, Z. A., Chiang, G. G., Alaimo, P J.. Kenski, D. M., Ho, C. B., Coan, K., Abraham, R. T. and Shokat, K. M. (2004) Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg, Med. Chem. 12, 4749-4759
20. Raynaud, F. I., Eccles, S., Clarke, P. A., Hayes, A., Nutley, B., Alix, S., Henley, A., Di-Stefano, F, Ahmad, Z., Guillard, S. et al. (2007) Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res. 67, 5840-5850
21. Sachu, C., Dick, K., Tino, W. T. and Staunton, D. E. (2003) Selective role of PI3Kδ in neutrophil inflammatory responses. Biochem. Biophys. Res. Commun. 308, 764-769
22. Puri, K. D., Doggett, T. A., Douangpanya, J., Hou, Y., Tino, W. T., Wilson, T., Graf, T., Clayton, E., Turner, M., Hayflick, J. S. and Diacovo, T. G. (2004) Mechanisms and implications of phosphoinositide 3-kinase δ in promoting neutrophil trafficking into inflamed tissue. Blood 103, 3448-3456
23. Condliffe, A. M., Davidson, K., Anderson, K. E., Ellson, C. D., Crabbe, T., Okkenhaug, K., Vanhaesebroeck, B., Turner, M., Webb, L.. Wymann, M. P. et al. (2005) Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 106, 1432-1440
24. Sawyer, C., Sturge, J., Bennett, D. C., O'Hare, M. J., Allen, W. E., Bain, J., Jones, G. E. and Vanhaesebroeck, B. (2003) Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110δ. Cancer Res. 63, 1667-1675
25. Sujobert, F., Bardet, V, Cornillet-Lefebvre. F., Hayflick, J. S., Prie, N., Verdier, F., Vanhaesebroeck, B.. Muller, O., Pesce, F, Itrah, N. et al. (2005) Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 106, 1063-1066
26. Jackson, S. P., Schoenwaelder, S. M., Goncalves, I., Nesbitt, W. S., Yap, C. L., Wright, C. E., Kenche, V., Anderson, K. E., Dopheide. S. M., Yuan, Y. et al. (2005) PI3-kinase p110β: a new target for antithrombotic therapy. Nat. Med. 11, 507-514
27. Foukas, L. C., Claret, M., Pearce, W., Okkenhaug, K., Meek, S., Peskett, E., Sancho, S., Smith, A. J., Withers, D. J. and Vanhaesebroeck, B. (2006) Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441, 366-370
28. Taylor, V., Wong, M., Brandts, C., Reilly, L., Dean, N. M., Cowsert, L. M., Moodie, S. and Stokoe, D. (2000) 5′ Phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells. Mol. Cell. Biol. 20, 6860-6871
29. Li. Z., Jiang, H., Xie, W., Zhang. Z., Smrcka, A. V. and Wu, D. (2000) Roles of PLC-β2 and -β3 and PI3Kγ in chemoattractant-mediated signal transduction. Science 287, 1046-1049
30. Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T, Clark, L., Bayani, N., Coppe, J. R, Tong, F. et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515-527
31. Sarbassov, D. D., Guertin, D. A., Ali, S. M. and Sabatini, D. M. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101
32. Pende, M., Um, S. H., Mieulet, V., Sticker, M., Goss, V. L., Mestan, J., Mueller, M., Fumagalli, S., Kozma, S. C. and Thomas, G. (2004) S6K1-/ -/S6K2-/- mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol. Cell. Biol. 24, 3112-3124
33. Roux, P. P., Shahbazian, D., Vu, H., Holz, M. K., Cohen, M. S., Taunton, J., Sonenberg, N. and Blenis, J. (2007) RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J. Biol. Chem. 282, 14056-14064
34. Lu, Y., Lin, Y. Z., LaPushin, R., Cuevas, B., Fang, X., Yu, S. X., Davies, M. A., Khan, H., Furui, T, Mao, M. et al. (1999) The PTEN/ MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene 18, 7034-7045
35. Ferrell, Jr, J. E. and Machleder, E. M. (1998) The biochemical basis of an all-or-none cell fate switch in Xenopus oocytes. Science 280, 895-898
36. Kozma, S. C., Bogaard, M. E., Buser, K., Saurer, S. M., Bos, J. L., Groner, B. and Hynes, N. E. (1987) The human c-Kirsten ras gene is activated by a novel mutation in codon 13 in the breast carcinoma cell line MDA-MB231. Nucleic Acids Res. 15, 5963-5971
37. Kraus, M. H., Yuasa, Y. and Aaronson, S. A. (1984) A position 12-activated H-ras oncogene in all HS578T mammary carcinosarcoma cells but not normal mammary cells of the same patient. Proc. Natl. Acad. Sci. U.S.A. 81, 5384-5388
38. Cohen, M. S., Zhang, C., Shokat, K. M. and Taunton, J. (2005) Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 308, 1318-1321
39. Sawyers, C. L. (2003) Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev. 17, 2998-3010
40. Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S. L., Herbst, R. S., Ince, W. L., Janne, P. A., Januario, T., Johnson, D. H. et al. (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23, 5900-5909
41. Tsao, M. S., Sakurada, A., Cutz, J. C., Zhu, C. Q., Kamel-Reid, S., Squire, J., Lorimer, I., Zhang, T., Liu, N., Daneshmand, M. et al. (2005) Erlotinib in lung cancer: molecular and clinical predictors of outcome. N. Engl. J. Med. 353, 133-144
42. Flaherty, K. (2005) Phase II trials of BAY 43-9006 alone and in combination with chemotherpay alone in metastatic melanoma, 6th World Congress on Melanoma, Vancouver, BC, Canada, 6-10 September 2005, Abstract 049
43. Tsutsui, S., Inoue, H., Yasuda, K., Suzuki, K., Higashi, H., Era, S. and Mori, M. (2005) Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast. Oncology 68, 398-404
44. Garcia, J. M., Silva, J. M., Dominguez, G., Gonzalez, R., Navarro, A., Carretero, L., Provencio, M., Espana, P. and Bonilla, F. (1999) Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res. Treat. 57, 237-243
45. Trotman, L. C., Wang, X., Alimonti, A., Chen, Z., Teruya-Feldstein, J., Yang, H., Pavletich, N. P., Carver, B. S., Cordon-Cardo, C., Erdjument-Bromage, H. et al. (2007) Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 128, 141-156
46. Martelli, A. M., Borgatti, P., Bortul, R., Manfredini, M., Massari, L., Capitani, S. and Neri, L. M. (2000) Phosphatidylinositol 3-kinase translocates to the nucleus of osteoblast-like MC3T3-E1 cells in response to insulin-like growth factor I and platelet-derived growth factor but not to the proapoplotic cytokine tumor necrosis factor α. J. Bone Miner. Res. 15, 1716-1730
47. Schwarzer, R., Tondera, D., Arnold, W., Giese, K., Klippel, A. and Kaufmann, J. (2005) REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase. Oncogene 24, 1138-1149
48. Chen, J. S., Zhou, L. J., Entin-Meer, M., Yang, X., Donker, M., Knight, Z. A., Weiss, W., Shokat, K. M., Haas-Kogan, D. and Stokoe, D. (2008) Characterization of structurally distinct, isoform-selective phosphoinositide 3′-kinase inhibitors in combination with radiation in the treatment of glioblastoma. Mol. Cancer Ther. 7, 841-850
49. Pao, W., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G. and Varmus, H. E. (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2, e17
50. Haas-Kogan, D. A., Prados, M. D., Tihan, T., Eberhard, D. A., Jelluma, N., Arvold, N. D., Baumber, R., Lamborn, K. R., Kapadia, A., Malec, M. et al. (2005) Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl. Cancer Inst. 97, 880-887
51. Fan, Q. W., Specht, K. M., Zhang, C., Goldenberg, D. D., Shokat, K. M. and Weiss, W. A. (2003) Combinatorial efficacy achieved through two-point blockade within a signaling pathway: a chemical genetic approach. Cancer Res. 63, 8930-8938
52. Gottschalk, A. R., Doan, A., Nakamura, J. L., Haas-Kogan, D. A. and Stokoe, D. (2005) Inhibition of phosphatidylinositol-3-kinase causes cell death through a protein kinase B (PKB)-dependent mechanism and growth arrest through a PKB-independent mechanism. Int. J. Radiat. Oncol. Biol. Phys. 61, 1183-1188